Literature DB >> 6138935

beta-adrenoceptor blockade and physical activity: cardiovascular and metabolic aspects.

G Koch, I W Franz, A Gubba, F W Lohmann.   

Abstract

This paper assesses mechanisms that may contribute to the higher incidence of increased muscle fatigue during exercise and reduced exercise performance as observed with selective compared with non-selective beta-adrenoceptor antagonists. Published data and the results obtained in 8 healthy subjects (mean age 23 years) studied before and after acute beta-adrenoceptor blockade with pindolol (nonselective, 10 mg) and metoprolol (beta 1-receptor selective, 100 mg) suggest that the differences in the cardiovascular and respiratory effects between the 2 types of antagonists are marginal and cannot explain the discrepancies concerning exercise perception and performance. Conversely, basic differences between the 2 types of antagonists were shown in different groups of hypertensive men (mean age 32 years) studied before and after 4 weeks of treatment with pindolol (15 mg), and with metoprolol (200 mg) and acebutolol (cardioselective, 500 mg), by single crossover technique. Whereas lipolysis was similarly inhibited by both selective and non-selective antagonists, hypoglycaemia occurred only under non-selective blockade. It apparently reflects the inhibition of glycogen breakdown; concomitant rises in plasma adrenaline and ACTH probably reflect counter-regulatory mechanisms.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6138935     DOI: 10.1111/j.0954-6820.1983.tb01614.x

Source DB:  PubMed          Journal:  Acta Med Scand Suppl        ISSN: 0365-463X


  5 in total

Review 1.  Exercise metabolism and beta-blocker therapy. An update.

Authors:  A Head
Journal:  Sports Med       Date:  1999-02       Impact factor: 11.136

Review 2.  Exercise performance and beta-blockade.

Authors:  P A Tesch
Journal:  Sports Med       Date:  1985 Nov-Dec       Impact factor: 11.136

3.  Responses of glomerular filtration, renal blood flow and salt-water handling to acute cardioselective and non-selective beta-adrenoceptor blockade in essential hypertension.

Authors:  G Koch; L Fransson; L Karlegärd; P Kothari
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 4.  Acebutolol. A review of its pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia.

Authors:  B N Singh; W R Thoden; A Ward
Journal:  Drugs       Date:  1985-06       Impact factor: 9.546

5.  Working ability and exercise tolerance during treatment of a mild hypertension. I. Comparison between a beta-adreno-receptor blocking drug and a calcium antagonist.

Authors:  K Lange Andersen; W Piatkowski; K A Green; W Ottmann
Journal:  Int Arch Occup Environ Health       Date:  1985       Impact factor: 3.015

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.